29 results about "Intestinal permeability" patented technology

We are disclosing derivatives of 5-hydroxylated polymethoxyflavones. The derivatives offer enhanced oral bioavailability and improved intestinal permeability. The derivatives of the invention release the biologically active 5-hydroxylated polymethoxyflavones that are activated by chemical or enzymatic processes in the GI Tract. The derivatives are constructed as bioreversible prodrugs containing the bioactive molecules covalently linked with lipids like fatty acids, glycerides or phospholipids. The derivatives are useful against inflammatory conditions and aging. Formulations including the derivatives are also disclosed.

This invention belongs to the field of feed preparation technology, specifically disclosing a feed composition suitable for Aohan donkeys and its application in fattening. The feed composition comprises the following raw materials in parts by weight: 25-35 parts of compound fermented product, 0.5-2 parts of camellia extract, 30-40 parts of corn stalks, and 5-10 parts of cottonseed meal. This invention discloses a feed composition suitable for Aohan donkeys and its application in fattening. This feed composition can increase the body weight and average daily weight gain of Aohan donkeys, reduce intestinal permeability indicators, improve intestinal barrier function, promote the growth and development of Aohan donkeys, and improve the meat quality of Aohan donkeys.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

The invention discloses an in-vitro drug intestinal permeability determination method based on a high-flux barrier chip, and belongs to the technical field of microfluidics and organ chips. The high-flux barrier chip adopts a three-layer structural design of a pore plate layer, a porous membrane layer and a channel layer; the porous membrane not only realizes physical separation of the pore plate layer and the channel layer, but also undertakes the core function of interlayer substance exchange, and by matching with a gravity flow driving system provided by the swing table, the fluid dynamic characteristics in the chip are guaranteed. The hole pitch of the chip is strictly matched with the standard of a commercialized pore plate, and the chip can be directly compatible with various conventional analytical instruments and has good universality. The method is suitable for determining the intestinal permeability of the passive transport compound which can be absorbed by intestinal cells. Compared with the prior art, the human intestinal cells are adopted to construct the chip model, animal experiments do not need to be carried out, related ethical disputes are thoroughly avoided, the whole operation process is simple and easy to implement, and the detection time is greatly shortened.

The invention discloses a compound and application thereof in preparation of a medicine for treating Alzheimer disease. The invention provides a method for constructing a disease animal model by using N-oleoyldopamine (OLDA) and application of the model in drug screening and animal experiment research. The animal model comprises at least one animal model of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases. According to the application, based on OLDA, it is found that the compound has new application in the aspects of neurodegenerative diseases, intestinal permeability diseases and inflammatory diseases, and based on OLDA, the compound which plays a certain role in treating the diseases is screened out.

This invention discloses the application of a composition in the preparation of foods or medicines that reduce blood lead levels, belonging to the field of food or pharmaceutical applications. The composition is for improving intestinal microecology, comprising inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber, wherein the weight ratio of inulin, galactooligosaccharides, polydextrose, and water-insoluble dietary fiber is 25:25:20:30, and the composition is taken immediately after being dissolved in warm water before meals. This invention, through the rational combination of water-insoluble dietary fiber and functional polysaccharides, adjusts the release rate of nutrients in the intestine, slows down digestion, absorbs and eliminates toxic substances from food, reduces intestinal permeability, and simultaneously possesses the functions of water absorption and swelling, gradient adhesion, mechanical isolation, mesh adsorption, ion exchange, and microbial regulation, providing a favorable environment and food for the growth of intestinal microorganisms, and effectively reducing blood endotoxins and blood lead levels, enhancing immunity, and preventing chronic diseases.

The invention discloses a feed additive for improving pathogen resistance and intestinal injury of high-fat fed fishes and application of the feed additive, and belongs to the technical field of fish feed. The feed additive is indole-3-propionic acid, and the application of the feed additive is that IPA is added into a high-fat feed according to the addition amount of 20-160 mg / kg. Experiments find that IPA with different concentrations can significantly improve the aeromonas hydrophila infection resistance of tilapia fed with high fat, enhance the intestinal immune enzyme activity, improve the intestinal permeability, enhance the intestinal antioxidant ability and relieve intestinal inflammation. The IPA disclosed by the invention can be used as a novel feed additive, can effectively relieve the problems of pathogen resistance reduction and intestinal injury of high-fat fed fishes, and has a good application prospect.

The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

This invention relates to the field of pharmaceutical technology, specifically to the application of porcine deoxycholic acid (HDCA) in the preparation of a drug for alleviating colitis. The dosage of HDCA is 50-200 mg / kg body weight / day. The colitis referred to is DSS-induced colitis, inflammatory bowel disease, or ulcerative colitis. Administration is by gavage. The drug alleviates colitis by promoting the proliferation of intestinal stem cells and / or repairing intestinal barrier function. This method can reverse the decrease in food intake and body weight in mice under DSS, reduce their disease activity index, and alleviate the problem of DSS-induced colon shortening in mice; simultaneously, HDCA also promotes the proliferation of intestinal stem cells, repairs intestinal permeability, and alleviates DSS-induced damage to the intestinal mucosal barrier function in mice. It can inhibit the expression of intestinal inflammation-related genes in mice, alleviating inflammatory complications. It helps to reshape the intestinal flora of mice, especially promoting Akkermansia colonization and alleviating intestinal barrier damage.

The present invention relates to a Lactobacillus reuteri, and use, composition, drug and food thereof. The Lactobacillus reuteri has an accession number of CGMCC No. 21577, can improve intestinal flora disorder, reduce intestinal injury, improve intestinal permeability and promote immune system recovery, and has effects of treating or preventing allergic reactions of nervous system-related diseases such as autism, hyperactivity, tics, depression, etc.

This invention relates to the application of *Bifidobacterium longum* BL21 in the preparation of formulations to alleviate multi-organ damage induced by cisplatin chemotherapy, namely, a novel microbial strategy for preventing or alleviating multi-organ damage induced by cisplatin chemotherapy. This invention creatively discovers that *Bifidobacterium longum* BL21 can alleviate kidney damage, intestinal damage, and bone marrow suppression without interfering with the antitumor activity of cisplatin. Specifically, it can reverse the increase in serum creatinine and blood urea nitrogen levels caused by cisplatin chemotherapy, reverse the increase in inflammatory factor levels in kidney tissue caused by cisplatin chemotherapy, and alleviate oxidative stress damage in kidney tissue caused by cisplatin chemotherapy; it can reverse the increase in intestinal permeability caused by cisplatin chemotherapy, reverse the downregulation of intestinal tight junction protein expression caused by cisplatin chemotherapy, reverse the increase in serum endotoxin levels caused by cisplatin chemotherapy, and reverse the decrease in beneficial intestinal bacteria caused by cisplatin chemotherapy; it can improve hematopoietic dysfunction caused by cisplatin chemotherapy and restore white blood cell count.

The present application relates to the field of biological medicine and functional food, and discloses a kind of nutrition composition based on marine shrimp peptide for anti-obesity and improving metabolic syndrome;Including: Chinese tube whip shrimp peptide active component and pharmaceutically acceptable adjuvant, the Chinese tube whip shrimp meat protein is used as raw material, and the Chinese tube whip shrimp meat protein is prepared by alkaline protease enzymolysis, and the Chinese tube whip shrimp meat protein contains peptide segment with molecular weight less than 1 kDa, and APPPPP, HPPPP and MPLPP can be detected.The pharmaceutical composition can reduce the weight and fat tissue weight under the state of obesity, improve dyslipidemia, abnormal liver function and liver steatosis, reduce oxidative stress level, improve intestinal mucosal barrier damage and intestinal permeability increase, and regulate intestinal flora structure change.The active component in the present application is clear in origin, and the preparation process is clear, has the synergistic effect from lipid metabolism regulation, liver protection to intestinal barrier improvement, and can be used for preparing medicine for preventing or treating obesity and improving metabolic syndrome.

The present invention provides probiotic compositions and methods for improving animal health. The probiotic compositions include one or more isolated strains of Lactobacillus reuteri which colonizes the gastrointestinal tract to increase the health of an animal, including to alleviate the effects of chronic alcohol consumption, leaky gut, increased intestinal permeability and inflammation and treat or prevent alcohol-associated intestinal dysbiosis, leaky gut, increased intestinal permeability and inflammation, including intestinal inflammation associated with inflammatory bowel disease.

Disclosed in the present invention is the use of a water extract of Amomi fructus and / or a vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia. Further disclosed in the present invention is the use of the water extract of Amomi fructus and / or the vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia, or a drug for preventing and / or treating proteinuria caused by preeclampsia, or a drug for reversing a reduction in placental weight caused by preeclampsia, or a drug for restoring fetal intrauterine growth restrictions caused by preeclampsia, or a drug for restoring pathological damage to placental tissue or placental dysfunction caused by preeclampsia, or a drug for reversing the reduction in placental efficiency caused by preeclampsia, or a drug for repairing colonic barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching the intestinal tract of a patient with preeclampsia with Bifidobacterium bifidum. The present invention overcomes the limitations of current drugs for treating preeclampsia which exhibit limited single therapeutic effects and gastrointestinal adverse reactions.

This invention discloses a class of dendritic lipopeptide molecules that promote the oral absorption of macromolecular drugs, their preparation method, and applications. The dendritic lipopeptide molecules are formed by combining a hydrophilic head and a hydrophobic tail. The hydrophilic head consists of lysine and glutamic acid linked by amide bonds, while the hydrophobic tail is composed of organic carbon chains or fluorinated chains. The oral absorption enhancer used in this invention exhibits amphoteric characteristics, possessing excellent anti-protein adsorption capabilities, superior mucus penetration and small intestinal permeability, and good biocompatibility due to its amino acid element construction. The oral absorption enhancer used in this invention can cross multiple barriers, including the mucus layer and intestinal epithelial cells, without opening tight junctions, facilitating efficient and safe oral encapsulation and delivery of proteins.

The invention relates to the technical field of functional food processing, in particular to a method for enhancing intestinal barrier function regulating activity of galactooligosaccharide based on collagen peptide Maillard coupling and application of the method. According to the method for enhancing the intestinal barrier regulating activity of the galactooligosaccharide based on Maillard coupling of the collagen peptide, provided by the invention, the biological effect of the galactooligosaccharide in the aspect of regulating the intestinal barrier function can be remarkably improved; meanwhile, the obtained Maillard conjugate has remarkable advantages in the aspects of promoting mucous secretion of goblet cells, up-regulating expression of tight junction proteins ZO-1 and Occludin and reducing intestinal permeability. The method provided by the invention is simple and convenient to operate, industrialization is easy to realize, the obtained product can be used as a functional component related to intestinal health to be applied to the fields of food, functional food and the like, and the application value of galactooligosaccharide can be effectively improved.

The present invention relates to a biomarker composition for diagnosing psoriasis, comprising a Clostridium leptum strain as an active ingredient. It has been confirmed that the relative intestinal abundance of the strain is significantly reduced in a psoriasis patient group in comparison to that of a normal group, and the strain is effective in alleviating psoriasis symptoms and improving intestinal permeability, and thus can be effectively used as a composition for diagnosing, preventing, treating, or alleviating psoriasis.

This invention relates to the fields of nanotechnology, food science, and biomedicine, specifically to a zein-pectin composite nanoparticle loaded with naringin, its preparation method, and its application. The method includes the following steps: (1) dissolving zein and naringin in an alcohol-water solution to obtain a first solution; dissolving pectin in water to obtain a second solution; (2) adding the first solution to the second solution under stirring conditions. The average diameter of the composite nanoparticles conforms to the size range of nanodelivery systems, exhibiting excellent colloidal stability even under extreme environmental conditions; it also possesses good intestinal permeability and improved gastrointestinal bioavailability, and demonstrates potent antioxidant activity in vitro; furthermore, in cell models, the composite nanoparticles effectively alleviated oxidative stress, reduced free fatty acid-induced hepatocyte damage, and regulated lipid metabolism.

This invention discloses a quinolinate phosphoribosyltransferase (quinolinate phosphoribosyltransferase) intestinal function improvement product and its preparation method. The quinolinate phosphoribosyltransferase intestinal function improvement product includes quinolinate phosphoribosyltransferase. Based on the data from the test cases, it can be seen that oral administration of the quinolinate phosphoribosyltransferase intestinal function improvement product can intervene in the intestinal quinolinate phosphoribosyltransferase level, enhance the intestinal mucosal barrier function, maintain normal intestinal permeability, and alleviate intestinal immune dysfunction and intestinal inflammation.

The present invention relates to a composition for preventing, ameliorating or treating inflammatory bowel disease, comprising a germinated oat extract, which has improved intestinal permeability and tight junction integrity in the inflammatory intestinal environment, and which can be used for preventing, ameliorating or treating inflammatory bowel disease. Therefore, the compound can be used for preparing medicines, health-care functional foods, foods or prebiotics for preventing, improving or treating inflammatory bowel diseases.

The application provides application of indole-3-lactic acid in improving immunity of sea cucumber and inhibiting virulence factors of Vibrio splendidus. The application is used for preparing a product for inhibiting virulence factors of Vibrio, and a product for improving immune defense ability of aquatic animals; wherein the aquatic animals are preferably sea cucumber, and the Vibrio is preferably Vibrio splendidus. Researches show that under the premise of basically not affecting the growth of Vibrio splendidus, the indole-3-lactic acid can significantly reduce hemolytic activity, protease activity, motility and biofilm formation of the Vibrio splendidus, and can reduce intestinal permeability of the sea cucumber, repair intestinal physical barrier, relieve excessive inflammatory response induced by Vibrio splendidus infection, thereby improving survival rate of the sea cucumber after attack and reducing incidence probability. The technology has the advantages of small dosage, clear effect, green safety and low drug resistance selection pressure, and is suitable for prevention and control of sea cucumber skin rot syndrome.

The present application relates to the technical field of biopharmaceuticals, and particularly relates to a siRNA targeting ADAM17 gene based on intestinal barrier repair and application thereof in improving visceral hypersensitivity of IBS. The siRNA silences ADAM17 expression, inhibits abnormal cleavage of IL-10 receptor alpha subunit (IL-10RA) on the membrane of intestinal epithelial cells, maintains the integrity of the membrane-bound IL-10 receptor, restores IL-10 protective signaling, up-regulates tight junction proteins such as ZO-1 and Occludin, reduces intestinal permeability, repairs intestinal mucosal barrier, and finally improves colorectal distension-induced pain threshold and relieves visceral hypersensitivity. Animal model experiments show that the siRNA can significantly reduce the expression of ADAM17 protein in the colon, improve the structure and function of the barrier, and increase the pain threshold, and has application prospects as a new molecular targeted treatment for IBS.

The present application relates to a kind of synbiotic preparation, comprising: probiotic or its bacterial lysate, fermentation product, wherein probiotic is one or more selected from the following group: Bifidobacterium, Streptococcus, Lactobacillus, Saccharomycete, Escherichia coli;Prebiotic is one or more selected from the following group: breast milk oligosaccharide, fructo-oligosaccharide, inulin, lactulose, galacto-oligosaccharide, soybean oligosaccharide, resistant dextrin, xylo-oligosaccharide, isomalto-oligosaccharide, chitooligosaccharide;And wall material;The probiotic or its bacterial lysate, fermentation product is coupled with prebiotic, and wall material is wrapped in the coupling product.The synbiotic preparation of the application is simple, no chemical drug or antibiotic component is added, can repair damaged intestinal mucosal barrier, reduce intestinal permeability, regulate immune balance, optimize flora structure, so as to more effectively treat colitis.In addition, it is convenient to use, easy to promote in farm.

The present invention relates to a composition comprising a germinated oat (Avena sativa L.) extract for preventing, alleviating or treating inflammatory bowel diseases. The composition improves intestinal permeability and improves tight junction integrity in an inflammatory intestinal environment, and thus can be effectively used in the preparation of medicines, health functional foods, foods or prebiotics for preventing, alleviating or treating inflammatory bowel diseases.

The invention discloses a preparation method and application of oral microspheres containing chlorella and ginseng polysaccharide, and belongs to the technical field of biological medicine. The oral microspheres are prepared in a water-in-oil manner by utilizing a microfluidic technology, the microspheres are loaded with chlorella and ginseng polysaccharide, and a thermal response gel network is formed by taking methylacryloylated gelatin as a carrier. The prepared microspheres are stable in the stomach environment, can be gelated and gradually degraded under the induction of temperature in the intestinal tract after being orally taken, and slowly release active ingredients, so that the intestinal targeted delivery efficiency of the microspheres is effectively improved. The oral microspheres have multiple functions of regulating intestinal flora, repairing intestinal barriers, reducing intestinal permeability and regulating system immunity, and can remarkably improve intestinal and joint pathological manifestations related to rheumatoid arthritis. Furthermore, the joint cavity injection glucocorticoid is combined, so that the synergistic treatment of intestinal tracts and joints can be realized, and the anti-inflammatory and tissue protection effects are enhanced. The system is good in safety and stable in preparation process, and has wide application potential in rheumatoid arthritis and other chronic inflammatory diseases.

The invention discloses an application of a muscle nutrient inhibitor in preparation of a medicine for preventing and treating inflammatory bowel diseases or conditions thereof. The muscle nutrient inhibitor comprises at least one of nucleic acid, an antibody or a fragment thereof, a small molecule compound, protein, polypeptide and enzyme. The muscle nutrient inhibitor provided by the invention can reduce the amount or activity of muscle nutrients, further reduce the intestinal permeability and increase the expression of tight junction protein ZO-1, thereby effectively relieving intestinal inflammation and repairing the intestinal barrier function.

This invention belongs to the field of feed additive preparation technology, specifically disclosing a compound vitamin preparation, its preparation method, and its application. The compound vitamin preparation comprises the following components by weight: 5-10 parts of Sophora japonica flower extract, 1-2 parts of vitamin A, 1-2 parts of vitamin C, 1-2 parts of vitamin E, and 20-30 parts of porous starch. This invention discloses a compound vitamin preparation, its preparation method, and its application. This compound vitamin preparation can increase animal body weight and average daily weight gain, reduce intestinal permeability indicators, improve intestinal barrier function, and promote animal growth and development.

Chronic inflammatory bowel disorders (IBDs) are characterized by altered intestinal permeability, prompting inflammatory, oxidative stress and immunological factors. Gut microbiota disorders impact brain function via the bidirectional gut-brain axis, influencing behavior through inflammatory cascades, oxidative stress, and neurotransmitter levels. The present invention comprises lyophilized milk kefir alone and lyophilized milk kefir as solid carriers loaded with self-nanoemulsifying self-nanosuspension (SNESNS) of licorice extract. Daily administration of lyophilized milk kefir loaded with SNESNS restores normal body weight and intestinal mucosa while significantly reducing submucosal inflammatory cell infiltration, leading to significant alleviation of neurotransmitter levels and improved memory functions, thereby addressing gut-brain axis disorders. Additionally, it normalized fecal microbiome constituents, inflammatory cytokine levels, and oxidative stress in examined tissues and serum. Moreover, daily administration of kefir-loaded SNESNS normalizes the disease activity index, alleviates histopathological changes induced by IBD induction, and partially restored the normal gut microbiota. These alterations are associated with improved cognitive functions, attributed to the maintenance of normal neurotransmitter levels and alleviation of triggered inflammatory factors and oxidative stress levels.